Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)
Cartesian Therapeutics (RNAC) reported Tax Provisions of -$288000.0 for Q4 2022, down 308.7% year-over-year from $138000.0 in Q4 2021, and up 10.28% on a QoQ basis from -$321000.0 in Q3 2022.
Cartesian Therapeutics (RNAC) has 2 years of Tax Provisions data on file, last reported at -$288000.0 in Q4 2022.
- Quarterly Tax Provisions fell 308.7% year-over-year to -$288000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $15.4 million (down 3.81% YoY) and the FY2025 annual result came in at -$9.2 million, down 3164.33% from the prior year.
- Tax Provisions advanced to -$288000.0 in Q4 2022 per RNAC's latest filing, from -$321000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $15.8 million in Q3 2021 and bottomed at -$321000.0 in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Cartesian Therapeutics | 202.49 Mn | 202.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -288,000.00 |
| Sep 30, 2022 | -321,000.00 |
| Dec 31, 2021 | 138,000.00 |
| Sep 30, 2021 | 15.83 Mn |